# A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

> **NCT05624710** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 25 (actual)

## Conditions studied

- Renal Insufficiency
- Kidney Diseases

## Interventions

- **DRUG:** INCB054707

## Key facts

- **NCT ID:** NCT05624710
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-08
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624710, "A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05624710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*